T. Sauer

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Relapsed or refractory acute myeloid leukemia (R/R AML) remains a therapeutic challenge, with standard high‑dose cytarabine-based salvage regimens achieving complete remission (CR) rates of around 50%. In the phase 1/2 RELAX trial, adding venetoclax (VEN) to high‑dose cytarabine and mitoxantrone (HAM) was considered sa...

IDH3 regulates citrate homeostasis to control metabolic fitness and venetoclax resistance of AML stem cells.

Functional characterization of snoRNA-derived RNA (sdRNA) expression in healthy hematopoiesis and acute myeloid leukemia.

SDRNAs are introduced as standalone regulatory effector molecules in healthy hematopoiesis and AML and proposed and characterized NUDT21, an important regulator of alternative polyadenylation and oncogenic gene expression, as a downstream target of sd3'-SNORD78 in AML.

Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment.

TFiT (tumor-reactive features in T cells), a transcriptional classifier that identifies tumor-reactive T cells and stratifies immunotherapy, but not chemotherapy, response across independent MM and AML cohorts, supporting its specificity for T cell-mediated tumor control.